<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ABACAVIR SULFATE</span><br/>(a-ba'ca-vir)<br/><span class="topboxtradename">Ziagen<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antiviral agent</span>; <span class="classification">antiretroviral agent</span>; <span class="classification">nucleoside reverse transcriptase inhibitor (nrti)</span><br/><b>Prototype: </b>Lamivudine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>300 mg tablets; 20 mg/mL oral solution</p>
<h1><a name="action">Actions</a></h1>
<p>Abacavir is a synthetic nucleoside analogue with inhibitory activity against HIV. It inhibits the activity of HIV-1 reverse
         transcriptase (RT) both by competing with the natural DNA nucleoside and by incorporation into viral DNA.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Abacavir prevents the formation of viral DNA replication. Therefore the viral load decreases as measured by an increased CD<sub>4</sub> lymphocyte cell count and suppression of HIV RNA, indicated by decreased HIV RNA copies, in HIV-positive individuals with
         little or no exposure to zidovudine (AZT).
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of HIV infection in combination with other antiretroviral agents.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to abacavir (fatal rechallenge reactions reported); lactic acidosis; creatinine clearance of 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Prior resistance to another nucleoside reverse transcriptase inhibitor (NRTI); hepatic dysfunction; older adults.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">HIV Infection</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 300 mg b.i.d.<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>3 mo16 y,</i> 8 mg/kg b.i.d. (max: 300 mg b.i.d.)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Tablets &amp; oral solution are interchangeable on a mg-for-mg basis.</li>
<li>Store tablets and liquid at 20°25° C (68°77° F). Liquid may be refrigerated.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Hypersensitivity reactions (including fever, skin rash, fatigue, nausea, vomiting, diarrhea, abdominal pain); malaise; lethargy;
      myalgia; arthralgia; paresthesia; edema; shortness of breath. <span class="typehead">CNS:</span> Insomnia, <span class="speceff-common">headache, fever</span>. <span class="typehead">CV:</span> Hypotension (associated with hypersensitivity reaction). <span class="typehead">GI:</span>
<span class="speceff-life">Hepatomegaly</span> with steatosis, <span class="speceff-common">nausea, vomiting, diarrhea, anorexia,</span> pancreatitis, increased GGT, increased liver function tests. <span class="typehead">Skin:</span>
<span class="speceff-common">Rash</span>. <span class="typehead">Other:</span> Lactic acidosis, renal insufficiency. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Alcohol</b> may increase abacavir blood levels. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed, 83% bioavailable. <span class="typehead">Distribution:</span> Distributes into extravascular space and erythrocytes; 50% protein bound. <span class="typehead">Metabolism:</span> Metabolized by alcohol dehydrogenase and glucuronyl transferase to inactive metabolites. <span class="typehead">Elimination:</span> 84% excreted in urine, primarily as inactive metabolites; 16% excreted in feces. <span class="typehead">Half-Life:</span> 1.5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of hypersensitivity: fever, skin rash, fatigue, GI distress (nausea, vomiting, diarrhea, abdominal pain).
            Withhold drug immediately &amp; notify physician if hypersensitivity develops.
         </li>
<li>Lab tests: Periodically monitor liver function, BUN and creatinine, CBC with differential, triglyceride levels, and blood
            glucose, especially in diabetics.
         </li>
<li>Withhold drug &amp; notify physician for S&amp;S of acidosis, hepatotoxicity, or renal insufficiency.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Take drug exactly as prescribed at indicated times. Missed dose: Take immediately, then resume dosing schedule. Do not double
            a dose.
         </li>
<li>Withhold drug immediately &amp; notify physician at first sign of hypersensitivity reaction (see Assessment &amp; Drug Effects).</li>
<li>Carry Warning Card provided with drug at all times.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>